Zhuhai Kerui Biotechnology (revision 41)

Zhuhai Kerui Biotechnology Co., Ltd. (trading as KP; keruipeptides.com) is a research-peptide supplier trading as KP from Zhuhai, Guangdong, China, incorporated in 2016, supplying research peptides and related materials with batch documentation and tracked international shipping.^[1][2]

The organisation is one of twenty covered on PeptidePedia under Project:Vendor notability. Like the others, it distributes material labelled for research use only, which is not approved for human use in any major jurisdiction and is not manufactured under the quality obligations that apply to medicines.^[3]

This article describes what is verifiable. Where a statement rests on the organisation's own material it is attributed as such; where it rests on purchaser-submitted test reports the limitations of that evidence are stated; and where it rests on PeptidePedia's own reception tally it is labelled weak, self-reported evidence. Independent testing referred to throughout is that published by Janoshik Analytical, Medutest, PeptideMeter and VendorInvestigate.^[4]

Incorporated in 2016 in Zhuhai, on the western side of the Pearl River Delta adjacent to Macau, the organisation operates from one of China's more established special economic zones.^[1] The location has a practical consequence visible in purchaser reports: outbound shipments frequently route through Hong Kong or Macau, and reported transit times to Europe and North America have been among the shorter in this set.^[5]

The documentary base is the registry record, the organisation's own material and purchaser reports. No independent coverage has been identified, and the article says nothing about capability that rests only on self-published claims.

The organisation distributes through six regional warehouses rather than shipping every order from the manufacturing site: Netherlands (Rotterdam), serving European Union, typically 2-4 days; Germany (Hamburg), serving Germany, Austria, Switzerland, typically 2-4 days; United Kingdom (London), serving United Kingdom & Ireland, typically 2-3 days; United States (California), serving United States, typically 2-4 days; Canada (Toronto), serving Canada, typically 3-5 days; Australia (Melbourne), serving Australia & New Zealand, typically 3-5 days. Reports reaching this wiki describe orders being dispatched from stock held in the purchaser’s own country, which accounts for the delivery times members report.

Reports describe lyophilised material in crimped glass vials with a batch certificate reporting purity, appearance and, in most of the submitted set, a water content.^[5] Insulated packaging with a gel pack is described for the incretin lines.

One documentation practice recorded across several reports is worth noting: certificates in this set have named the analytical method and column, which is uncommon. A purity figure with a stated method is more useful than one without, because area percent depends on the separation that produced it.^[6]

Method disclosure on the peptide lines is the distinguishing documentation feature. It does not make the figure correct; it makes it checkable, which is a different and more useful property.^[6]

Submitted reports on KP material to July 2026 are concentrated on the incretin analogues. Reported area percent figures have clustered in the high nineties, and because the accompanying certificates named the method, several purchasers were able to run a comparable separation rather than a merely similar one.^[5]

Where method conditions match, agreement between an independent report and a certificate is a meaningfully stronger observation than where they do not — much of the routine disagreement between two purity figures is attributable to different columns and integration parameters rather than to different material.^[6]

The PeptidePedia tally records 791 self-reported submissions to July 2026. Recurring positive themes are certificate detail, method disclosure and transit time; recurring complaints concern documentation on the bulk lines.^[4] Self-selected; reception rather than quality.^[4]

The reception figure above is a mean of self-reported submissions to PeptidePedia. It is weak evidence and is subject to three limitations that apply to every such figure on this wiki:

• Self-selection. People who submit are not a sample of purchasers. Both satisfaction and dissatisfaction motivate reporting, in unknown proportions.
• It measures reception, not quality. Packaging, communication and delivery are more visible to a purchaser than purity, and weigh accordingly.
• It is not comparable across communities. Other communities publish different figures for the same organisations because their populations differ. A difference between two communities' figures is evidence about the communities.^[4]

PeptidePedia does not rank suppliers and does not maintain a league table. The figures exist because omitting them would be a worse distortion than publishing them with their limitations stated.^[4]

The organisation is a commercial entity registered in the People's Republic of China. Nothing in the available record indicates a manufacturing authorisation, marketing authorisation or pharmacopoeial registration in any jurisdiction, and none should be inferred from a registered business scope, which is a licensing fact and not a quality assurance.^[1]

Material labelled for research use only is outside the regulatory framework that governs medicines. Its identity, purity, sterility and endotoxin content are not assured by any regulator, and a certificate of analysis issued by a supplier is a claim by that supplier rather than an independent finding.^[3][6]

Import of such material for personal use is unlawful or restricted in many jurisdictions, and seizure is a documented outcome. PeptidePedia describes the legal position and does not advise on it.^[3]

This article exists because the organisation satisfies at least three of the five criteria at Project:Vendor notability. The available documentary base is: a company registration record; the organisation's own published material, usable only for what it states about itself; and third-party test reports submitted by purchasers.^[1][2][5]

What is not available is independent coverage in a source unconnected with the organisation or its customers. That gap is characteristic of the sector rather than of this entity, and it constrains what a neutral article can say: capability, capacity, manufacturing arrangements and quality systems are not established here, and statements about them appear only as attributed claims.^[2]

• Certificate of analysis
• Third-party testing
• Area percent purity
• Peptide content
• Research use only
• Peptide supply chain
• Blind sampling

• Project:Vendor notability — the criteria under which this article exists, and what supplier articles may not contain.
• Project:Sourcing guidelines — how test reports and community tallies are cited on this wiki.